Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 26.05.2025 1 AJR Am J Roentgenol 1 Ann Oncol 2 Ann Surg Oncol 2 Ann Thorac Surg 2 BMC Cancer 1 Cancer 1 Clin Cancer Res 7 Clin Lung Cancer 1 Eur J Cardiothorac Surg 1 Eur Respir J 3 Int J Radiat Oncol Biol Phys 2 J Thorac Oncol 1 JAMA Oncol 1 Nat Med 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. HUANG WJ, Xie HB, Liu PP, Liu L, et al
   Pericardial Fat and Primary Tumor Radiomics for Predicting Occult N2 Disease and Survival in Clinical Stage I Non-Small Cell Lung Cancer: Multicenter Study With Biologic Correlation.
   AJR Am J Roentgenol. 2025 May 21. doi: 10.2214/AJR.25.32861.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. RIEDL JM, Fece de la Cruz F, Lin JJ, Parseghian C, et al
   Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors.
   Ann Oncol. 2025;36:682-692.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. NAEEM W, Khan AA, Seder CW
   ASO Author Reflections: Controversies at the Tumor Board-The Gray Areas in the Multimodality Treatment of Resectable Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2025 May 19. doi: 10.1245/s10434-025-17459.
   PubMed        
   
   
4. LI Z, Wu J, Chen C, Liu C, et al
   Longitudinal Trajectory of Patient-Reported Fatigue in Patients Undergoing Thoracoscopic Lung Cancer Surgery.
   Ann Surg Oncol. 2025 May 17. doi: 10.1245/s10434-025-17444.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

5. LIANG H, Wang W, Zhang M, Wang R, et al
   Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer.
   Ann Thorac Surg. 2025 May 15:S0003-4975(25)00420.
   PubMed         Abstract available
   
   
6. XIE S, Hu Q, Wu Z, Wang B, et al
   Clinical and Genetic Characteristics of Early-Onset Lung Adenocarcinoma in a Large Chinese Cohort.
   Ann Thorac Surg. 2025;119:1196-1204.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. YANG S, Liu Y, Zhao J, He Z, et al
   EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study.
   BMC Cancer. 2025;25:900.
   PubMed         Abstract available
   
   
8. HONG M, Yun I, Moon JY
   Impact of doctor-shopping behavior on patient survival in lung cancer: findings from a 11-year cohort study using Korean claims data.
   BMC Cancer. 2025;25:914.
   PubMed         Abstract available
   
   

   
   Cancer

9. GARG SK, Kohli K, Garg IK, Garg YK, et al
   Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
   Cancer. 2025;131:e35903.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

10. CHENG Y, Wang J, Yu Y, Wang Q, et al
    Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0022.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

11. LU C, Yan HH, Zhang CY, Chen SY, et al
    PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease.
    Clin Lung Cancer. 2025;26:263-266.
    PubMed         Abstract available
    
    
12. PALECKI J, Tucker M, Bernstein A, Melby G, et al
    Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in Philadelphia.
    Clin Lung Cancer. 2025 Apr 28:S1525-7304(25)00086.
    PubMed         Abstract available
    
    
13. WEI L, Lao Y, Fu T, Xie Z, et al
    Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Apr 23:S1525-7304(25)00078.
    PubMed         Abstract available
    
    
14. PINARD L, Ullur AR, Everest L, Zhan LJ, et al
    Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00059.
    PubMed         Abstract available
    
    
15. AHN JH, Choi SH, Park SH, Kim I, et al
    Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea.
    Clin Lung Cancer. 2025;26:314-323.
    PubMed         Abstract available
    
    
16. CORRE R, Decroisette C, Auliac JB, Falchero L, et al
    First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing >/= 50% PD-L1 (ESCKEYP GFPC 05-2018).
    Clin Lung Cancer. 2025;26:331-337.
    PubMed         Abstract available
    
    
17. GUTTA R, Teslow E, Jaeger E, Stoppler MC, et al
    Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers.
    Clin Lung Cancer. 2025;26:307-313.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

18. WERNER R, Eisenberg MA, Hooda Z, Ries S, et al
    Perioperative and long-term survival outcomes following resection of stage iv non-small-cell lung cancer: a multi-center experience.
    Eur J Cardiothorac Surg. 2025 May 20:ezaf156. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Eur Respir J

19. SELMAN M, Buendia-Roldan I, Pardo A
    Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis.
    Eur Respir J. 2025;65:2402418.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. OHRI N, Bodner WR, Kabarriti R, Shankar V, et al
    Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT).
    Int J Radiat Oncol Biol Phys. 2025;122:365-373.
    PubMed         Abstract available
    
    
21. ZHANG Y, Laine AM, Iyengar P, Westover KD, et al
    Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2025;122:374-382.
    PubMed         Abstract available
    
    
22. GAETA B, Eichholz JE, Walch H, Ilica AT, et al
    Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with SRS.
    Int J Radiat Oncol Biol Phys. 2025 Feb 8:S0360-3016(25)00093.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

23. RODE MM, Sykes AG, Allen MS, Ingalls LA, et al
    Risk-Based Lung Cancer Screening in Clinical Practice.
    J Thorac Oncol. 2025 May 14:S1556-0864(25)00717.
    PubMed         Abstract available
    
    
24. KREBS MG, Cho BC, Hiret S, Han JY, et al
    Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
    J Thorac Oncol. 2025 May 16:S1556-0864(25)00720.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

25. RICCIUTI B, Fusco F, Cooper A, Garbo E, et al
    Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 22. doi: 10.1001/jamaoncol.2025.1115.
    PubMed         Abstract available
    
    

    
    Nat Med

26. ZHENG MM, Zhou Q, Chen HJ, Jiang BY, et al
    Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases.
    Nat Med. 2025;31:1547-1556.
    PubMed         Abstract available
    
    

    
    PLoS One

27. PHILIBERT R, Beach SRH, Mills JA, Dawes K, et al
    Epigenetic assessments of alcohol consumption predict mortality in smokers at risk for lung cancer in the prostate, lung, colorectal and ovarian cancer screening trial.
    PLoS One. 2025;20:e0322783.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. WANG H, Huang J, Zhang Z, An Y, et al
    Phase separation of RXRgamma drives tumor chemoresistance and represents a therapeutic target for small-cell lung cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2421199122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.